GeorgeR.BlumenscheinJr.MD

Oncology • Houston, TX

Associate Professor of Medicine, University Tex Houston

Join to view full profile

Are you Dr. Blumenschein?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 103 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
1515 Holcombe Blvd
Houston, TX 77030
Phone+1 713-792-6161

Summary

Dr. George Blumenschein Jr., MD is an oncologist in Houston, Texas. He is currently licensed to practice medicine in Texas, Alabama, and Arizona. He is affiliated with University of Texas M.D. Anderson Cancer Center and is an Associate Professor of Medicine at University Tex Houston.

Education & Training

University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 1997 - 2000
University of Texas Health Science Center at HoustonResidency, Internal Medicine, 1994 - 1997
McGovern Medical School at UTHealthClass of 1994

Certifications & Licensure

FL State Medical License 2021 - Present
AZ State Medical License 2023 - 2026
TN State Medical License 2023 - 2026
TX State Medical License 1998 - 2026
WA State Medical License 2023 - 2026
AL State Medical License 2023 - 2025
GA State Medical License 2023 - 2025
LA State Medical License 2023 - 2025
MS State Medical License 2023 - 2025
OK State Medical License 2020 - 2025
American Board of Internal Medicine Medical Oncology
Join now to see all

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Cetuximab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Unresectable Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer Start of enrollment: 2004 Mar 01
Completed
Phase 2
BATTLE Program: Sorafenib in Patients With NSCLC Start of enrollment: 2006 Nov 01
Completed
Phase 2
Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer Start of enrollment: 2007 Apr 25
Active, not recruiting
Phase 2
Iressa Study in Patients With Salivary Gland Cancer Start of enrollment: 2004 May 01
Completed
Phase 2
BAY 43-9006 in Previously Untreated Patients With Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2006 May 01
Completed
Phase 1
A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2012 Nov 12
Terminated
Phase 1, Phase 2
Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer Start of enrollment: 2012 Jun 01
Completed
Phase 1, Phase 2
Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC
No longer available
Join now to see all

Publications & Presentations

PubMed

2 citations
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.
Ferdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, Yu Qian, Xin Sun
Nature. 2024-11-01
Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer.
Nicolas Zhou, Cheuk H Leung, William N William Jr, Annikka Weissferdt, Apar Pataer
Journal for Immunotherapy of Cancer. 2024-10-23
A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve-Mutant Metastatic Non-Small Cell Lung...
Xiuning Le, Jyoti D Patel, Elaine Shum, Christina Baik, Rachel E Sanborn
Journal of Clinical Oncology. 2024-10-08